Last reviewed · How we verify
Malignant Melanoma with BRAF V600K Mutation
Approved treatments
- Mekinist · Novartis
Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Malignant Melanoma with BRAF V600K Mutation patent landscape — cliff calendar, originator estates, attackable patents
- Malignant Melanoma with BRAF V600K Mutation treatment landscape brief
- Malignant Melanoma with BRAF V600K Mutation treatment updates RSS
Frequently asked questions about Malignant Melanoma with BRAF V600K Mutation
What drugs treat Malignant Melanoma with BRAF V600K Mutation?
Tracked treatments include Mekinist.
What is the treatment for Malignant Melanoma with BRAF V600K Mutation?
Standard treatment for Malignant Melanoma with BRAF V600K Mutation includes Mekinist. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Malignant Melanoma with BRAF V600K Mutation patent cliff · Malignant Melanoma with BRAF V600K Mutation CI report
- Treatment: Mekinist · Novartis
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing